new YORK (Reuters Health) – the review of three trials

randomized and controlled reveals that an experimental formula

that combines azelastine and fluticasone (MP29-02) is more effective

that the administration of one or another drug as therapy

intranasal rhinitis allergic seasonal (SAR) to.

“This provides for the first time strong clinical evidence

“

that antihistamines and intranasal corticosteroids

they are complementary in the pathogenesis pharmacological effects

“

of allergic rhinitis”, writes in Journal of Allergy and

Clinical Immunology the team of Dr. Warner Carr of Allergy

and Asthma Associates of Southern California.

The international team carried out three tests of 14 days each

one with 3,398 patients with RAE moderate to severe during

various allergy seasons.

After a first period of seven days, the participants

autoadministraron MP29-02 (137 mcg of azelastine/50 mcg of

fluticasone propionate) or 137 mcg of azelastine or 50 mcg of

fluticasone or a placebo. Made it every 12 hours, in each

nostril with a spray.

The authors combined the results of trials in a

meta-analysis, whose main result would be the reduction of

total Nasal symptoms, according to a scale of 0-24 points,

during the treatment period.

The reduction in the dose of MP29-02 (-5.7) was

significantly higher than that of fluticasone (- 5.1),

azelastine (- 4.4) or placebo (- 3).

“MP29-02 combination took 30 minutes to begin to

“

Act. “The clinical benefits arose the first day of

assessment remained during the whole treatment”, writes

the team.

Addition, in patients with more than 19 total points in the

rating scale of the symptoms at the beginning of the study, the

difference in reduction of symptoms between the formula

MP29-02 and fluticasone (-0.8) or azelastine (- 1,1) was more

in patients with less severe symptoms (differences of

– 0.6 and – 0.8, respectively).

“Together, these results show that the formula MP29-02

“

he could be considered the drug of first choice to treat

allergic rhinitis because it offers an additional benefit for

patients with the disease, especially when it is moderate

“

to severe”, concludes the team.

On 5 March, Meda, which is the company of Sweden that

develops the formula MP29-02 (which might be called Dymista)

reported through a statement that the administration of

Food and medicines of United States is analysing the

information presented.

Source: Journal of Allergy and Clinical Immunology, online

14 March 2012